mhurhangee/ep-ind-claims huggingface dataset:
A needle assembly comprising: a body having a proximal end, a distal end, and a channel located therebetween, said body being configured to be mounted to an injector; a needle fixed to said body, said needle having proximal and distal ends, said distal end extending distally from said distal end of said body and being formed for insertion into a patient, said proximal end of said needle being in communication with said channel; a filter disposed in the channel proximally of the proximal end of the needle; a second filter disposed proximally of, and spaced from, said filter in said channel; and a drug substance disposed in said channel proximally of said filter and distally of said second filter, wherein the overall porosity of said filter and the overall porosity of said second filter are configured to not permit passage therethrough of said drug substance; characterized in that said filter is porous and configured so that liquid located in the channel proximally of said filter may flow through said filter; and wherein said second filter is more porous than said filter, so that one or more secondary substances may be urged through the second filter more readily than through the filter. a body having a proximal end, a distal end, and a channel located therebetween, said body being configured to be mounted to an injector; a needle fixed to said body, said needle having proximal and distal ends, said distal end extending distally from said distal end of said body and being formed for insertion into a patient, said proximal end of said needle being in communication with said channel; a filter disposed in the channel proximally of the proximal end of the needle; a second filter disposed proximally of, and spaced from, said filter in said channel; and a drug substance disposed in said channel proximally of said filter and distally of said second filter, wherein the overall porosity of said filter and the overall porosity of said second filter are configured to not permit passage therethrough of said drug substance; characterized in that said filter is porous and configured so that liquid located in the channel proximally of said filter may flow through said filter; and wherein said second filter is more porous than said filter, so that one or more secondary substances may be urged through the second filter more readily than through the filter.
A method for adaptation of anaerobic microorganisms and selection of more oxygen tolerant anaerobic microorganisms, said method comprising the steps of culturing said microorganisms with a stepwise dual induction of oxidative stress via a stepwise increase of applied voltage and oxygen diffusion, and a stepwise reduction in the concentration of antioxidant combined with a stepwise increase in the concentration of oxidized counterpart to change the anti-oxidant/oxidized counterpart concentration ratio to adjust the redox state, wherein the dissolved oxygen concentration in the culture medium is maintained at a sub-lethal concentration at which some but not all of the microorganisms are killed.
A curable silicone composition for sealing an optical semiconductor element, comprising: an organopolysiloxane that has a viscosity at 25°C of 50 to 100,000 mPa·s, that has at least two silicon-bonded vinyl groups in one molecule, that has C 1-10 alkyl for the other silicon-bonded organic groups therein, and that lacks a siloxane unit represented by the following formula: SiO 4/2; an organopolysiloxane represented by the following average unit formula: (ViR 2 SiO 1/2) a (R 3 SiO 1/2) b (SiO 4/2) c (HO 1/2) d wherein Vi is a vinyl group; each R is independently a C 1-10 alkyl group; and a, b, c, and d are each positive numbers that satisfy: a + b + c = 1, a / (a + b) = 0.15 to 0.35, c / (a + b + c) = 0.53 to 0.62, and d / (a + b + c) = 0.005 to 0.03, at from 20 to 30 mass% of the total of components and; an organopolysiloxane that has at least three silicon-bonded hydrogen atoms in one molecule, that has C 1-10 alkyl for the silicon-bonded organic groups therein, and that contains from 0.7 to 1.6 mass% of silicon-bonded hydrogen atoms, in a quantity that provides from 0.8 to 2.0 moles silicon-bonded hydrogen atoms in this component per 1 mole of the total vinyl groups in components and; and a hydrosilylation reaction catalyst, in a quantity sufficient to cure the present composition, wherein a viscosity at 25°C of this composition lacking component is from 3,000 to 10,000 mPa·s and, letting η 25°C be this viscosity in mPa·s and letting η 100°C be a viscosity in mPa·s at 100°C of this composition lacking component, a value of the following formula: Log 10 η 100 ° C / Log 10 η 25 ° C is 0.830 to 0.870, where viscosity is determined in accordance with the method outlined in the description. an organopolysiloxane that has a viscosity at 25°C of 50 to 100,000 mPa·s, that has at least two silicon-bonded vinyl groups in one molecule, that has C 1-10 alkyl for the other silicon-bonded organic groups therein, and that lacks a siloxane unit represented by the following formula: SiO 4/2; an organopolysiloxane represented by the following average unit formula: (ViR 2 SiO 1/2) a (R 3 SiO 1/2) b (SiO 4/2) c (HO 1/2) d wherein Vi is a vinyl group; each R is independently a C 1-10 alkyl group; and a, b, c, and d are each positive numbers that satisfy: a + b + c = 1, a / (a + b) = 0.15 to 0.35, c / (a + b + c) = 0.53 to 0.62, and d / (a + b + c) = 0.005 to 0.03, at from 20 to 30 mass% of the total of components and; an organopolysiloxane that has at least three silicon-bonded hydrogen atoms in one molecule, that has C 1-10 alkyl for the silicon-bonded organic groups therein, and that contains from 0.7 to 1.6 mass% of silicon-bonded hydrogen atoms, in a quantity that provides from 0.8 to 2.0 moles silicon-bonded hydrogen atoms in this component per 1 mole of the total vinyl groups in components and; and a hydrosilylation reaction catalyst, in a quantity sufficient to cure the present composition,
Vehicle pneumatic tyre with a tread strip with at least one shoulder-side profile rib which is delimited by way of a circumferential groove which is configured to profile depth (T 1), in which profile rib a multiplicity of transverse grooves (3, 4) are configured which run parallel to one another, end at a spacing (a 1, a 2) of from 3.0 mm to 10.0 mm in front of the circumferential groove, and in each case have a groove bottom (3a, 4a) and an end flank (3b, 4b) which runs at the tread strip inner-side end of the transverse groove (3, 4) in a continuation of the groove bottom (3a, 4a) to the tread strip periphery, first transverse grooves and second transverse grooves being provided in the shoulder-side profile rib, the first transverse grooves ending at a spacing (a 1) in front of the circumferential groove, which spacing (a 1) is smaller than the spacing (a 2), at which the second transverse grooves end in front of the circumferential groove, first transverse grooves following second transverse grooves in an alternating manner in the circumferential direction, and a depression which protrudes into the profile rib and is open to the tread strip periphery being configured in the profile rib in the case of each second transverse groove, starting from the circumferential groove, characterized in that the end flank of every second transverse groove runs at an angle (γ) of from 20° to 45° with respect to the circumferential direction in a top view.
A process for producing triterpene alcohol, comprising sequentially conducting the following steps to: subjecting γ-oryzanol to alkaline hydrolysis; mixing the alkaline hydrolysate with a low polarity organic solvent selected from hydrocarbons and ethers, and extracting triterpene alcohol to obtain a triterpene alcohol-containing low polarity organic solvent; and adding water to the triterpene alcohol-containing low polarity organic solvent thus obtained, removing the low polarity organic solvent, and then melting triterpene alcohol in hot water having a temperature in the range of 85 to 100 °C, followed by cooling. subjecting γ-oryzanol to alkaline hydrolysis; mixing the alkaline hydrolysate with a low polarity organic solvent selected from hydrocarbons and ethers, and extracting triterpene alcohol to obtain a triterpene alcohol-containing low polarity organic solvent; and adding water to the triterpene alcohol-containing low polarity organic solvent thus obtained, removing the low polarity organic solvent, and then melting triterpene alcohol in hot water having a temperature in the range of 85 to 100 °C, followed by cooling.
A method of treating a substrate, comprising: providing a treatment space between at least two opposing electrodes, filling the treatment space with a gas composition, placing the substrate, which is a porous substrate, in the treatment space, generating an atmospheric pressure glow discharge plasma between the at least two opposing electrodes, and subjecting the porous substrate to the atmospheric pressure glow discharge plasma, thereby creating micro-pores uniformly throughout the porous substrate, wherein the treatment space comprises oxygen in the range of 0.1 to 21% vol.%, characterised in that the atmospheric pressure glow discharge plasma in the treatment space has a specific energy of 10 J/cm 2 or higher, and in that the method is performed with a duty cycle of 40% to 100%. providing a treatment space between at least two opposing electrodes, filling the treatment space with a gas composition, placing the substrate, which is a porous substrate, in the treatment space, generating an atmospheric pressure glow discharge plasma between the at least two opposing electrodes, and subjecting the porous substrate to the atmospheric pressure glow discharge plasma, thereby creating micro-pores uniformly throughout the porous substrate, wherein the treatment space comprises oxygen in the range of 0.1 to 21% vol.%, characterised in that the atmospheric pressure glow discharge plasma in the treatment space has a specific energy of 10 J/cm 2 or higher, and in that the method is performed with a duty cycle of 40% to 100%.
A phosphorus containing polyol, obtainable or obtained by a process comprising the reaction of at least one polyol with a phosphorus containing compound of the general formula: wherein X represents Cl, Br, I, alkoxy, or hydrogen, Y represents O or S, t is 0 or 1, R1 and R2 independently represent C1-C16-alkyl, C2-C16-alkenyl, C2-C16-alkynyl, C1-C16-alkoxy, C2-C16-alkenoxy, C2-C16-alkynoxy, C3-C10-cycloalkyl, C3-C10-cycloalkoxy, aryl, aryloxy, C6-C10-aryl-C1-C16-alkyl, C6-C10-aryl-C1-C16-alkoxy, C1-C16-alkyl- C6-C10-aryl, C1-C16-alkyl- C6-C10-aryloxy, wherein the phosphorus containing polyol comprises at least one phosphorus-containing group of the general formula: wherein Y represents O or S, t is 0 or 1, R1 and R2 independently represent C1-C16-alkyl, C2-C16-alkenyl, C2-C16-alkynyl, C1-C16-alkoxy, C2-C16-alkenoxy, C2-C16-alkynoxy, C3-C10-cycloalkyl, C3-C10-cycloalkoxy, aryl, aryloxy, C6-C10-aryl-C1-C16-alkyl, C6-C10-aryl-C1-C16-alkoxy, C1-C16-alkyl- C6-C10-aryl, C1-C16-alkyl- C6-C10-aryloxy, wherein the polyol is selected from the group of the polyether polyols, polyester polyols, and mixtures thereof, and wherein the phosphorus content of the phosphorous containing polyol is at least 7 % by weight, wherein the phosphorous containing polyol has an OH-functionality of from 2 to 4 and a molecular weight of from 100 to 700 g/mol. wherein X represents Cl, Br, I, alkoxy, or hydrogen, Y represents O or S, t is 0 or 1, R1 and R2 independently represent C1-C16-alkyl, C2-C16-alkenyl, C2-C16-alkynyl, C1-C16-alkoxy, C2-C16-alkenoxy, C2-C16-alkynoxy, C3-C10-cycloalkyl, C3-C10-cycloalkoxy, aryl, aryloxy, C6-C10-aryl-C1-C16-alkyl, C6-C10-aryl-C1-C16-alkoxy, C1-C16-alkyl- C6-C10-aryl, C1-C16-alkyl- C6-C10-aryloxy, Y represents O or S, t is 0 or 1, R1 and R2 independently represent C1-C16-alkyl, C2-C16-alkenyl, C2-C16-alkynyl, C1-C16-alkoxy, C2-C16-alkenoxy, C2-C16-alkynoxy, C3-C10-cycloalkyl, C3-C10-cycloalkoxy, aryl, aryloxy, C6-C10-aryl-C1-C16-alkyl, C6-C10-aryl-C1-C16-alkoxy, C1-C16-alkyl- C6-C10-aryl, C1-C16-alkyl- C6-C10-aryloxy,
Blocking agent comprising or consisting of cardanol and cardol in a weight ratio of 92:8 to 100:0 and at least one compound of general formula 1 in which R is C 17 H 33-n, where n = 0, 2 or 4, the compounds of formula 1 being present in a total amount of 0.1% to 3.0% by weight, preferably 1.0% to 3.0% by weight, more preferably 1.2% to 2.8% by weight, based on the total weight of the blocking agent and determined by the method indicated in the description, and optionally at least one compound of general formula 2 in which R is C 15 H 31-n, where n = 4 or 6, the compounds of formula 2, if present, being present in a total amount of not more than 1.8% by weight, preferably not more than 1.5% by weight, particularly preferably not more than 0.5% by weight, very particularly preferably not more than 0.1% by weight, based on the total weight of the blocking agent and determined by the method indicated in the description. cardanol and cardol in a weight ratio of 92:8 to 100:0 and at least one compound of general formula 1 in which R is C 17 H 33-n, where n = 0, 2 or 4, the compounds of formula 1 being present in a total amount of 0.1% to 3.0% by weight, preferably 1.0% to 3.0% by weight, more preferably 1.2% to 2.8% by weight, based on the total weight of the blocking agent and determined by the method indicated in the description, and optionally at least one compound of general formula 2 in which R is C 15 H 31-n, where n = 4 or 6, the compounds of formula 2, if present, being present in a total amount of not more than 1.8% by weight, preferably not more than 1.5% by weight, particularly preferably not more than 0.5% by weight, very particularly preferably not more than 0.1% by weight, based on the total weight of the blocking agent and determined by the method indicated in the description.
A composition comprising a pharmaceutically effective carrier, a GP2 peptide consisting of the amino acid sequence of SEQ ID NO:2 and granulocyte macrophage-colony stimulating factor, and wherein, other than the GP2 peptide, the composition does not contain any other HER2/ neu derived peptides, such as an E75 peptide having the amino acid sequence of SEQ ID NO:3, for use in preventing breast cancer recurrence in a subject, wherein the subject is human and is in remission following treatment with a standard course of therapy; and wherein cancer cells from the subject have an over-expression of HER2/ neu, and wherein the over-expression of HER2/ neu is an immunohistochemistry, "IHC" rating of 3 + or a fluorescence in situ hybridization, "FISH" rating of 2.0 or greater for HER2/ neu gene expression.
A belted disposable article comprising a chassis having first and second end portions (18, 14) and a central portion extending therebetween, and including a first covering layer having a first surface intended to face towards the user and a second surface intended to face away from the user in use, said article further comprising a pair of belt portions (16, 17) attached to the chassis so that a first belt portion and a second belt portion extending on each side of the first end portion of the chassis for securing to each other around a waist of a wearer of the article to form a belt having an exterior surface, wherein the first belt portion has a free end which carries a fastener adapted to be attached to an exterior surface of the other of the belt portions, and wherein said second end portion of the chassis comprises a fastening device (48, 49) for securing the second end portion of the chassis to the belt portion so that said article assumes a pant-like shape with the belt portions forming a part of a waist portion of the pant, said first and second belt portions (16, 17) being folded over said first surface to form a folded belt configuration prior to use of said article, whereby said first belt portion is arranged on top of the second belt portion, wherein a belt-opening trigger zone is disposed on the first belt portion and arranged adjacent the free end of the first belt portion, wherein a part of the free end adjacent a free end edge is distinguished from the remaining parts of the article by colour or pattern, and wherein the fastener is arranged on the first belt portion in between the belt-opening trigger zone and the free end. said first and second belt portions (16, 17) being folded over said first surface to form a folded belt configuration prior to use of said article, whereby said first belt portion is arranged on top of the second belt portion, wherein a belt-opening trigger zone is disposed on the first belt portion and arranged adjacent the free end of the first belt portion, wherein a part of the free end adjacent a free end edge is distinguished from the remaining parts of the article by colour or pattern, and wherein the fastener is arranged on the first belt portion in between the belt-opening trigger zone and the free end.
A system (60,70,80) comprising: a support structure configured to support a body (30,40,50,61), wherein the body (30,40,50,61) is rotatable with respect to the support structure; the body (30,40,50,61) including: a first runner (31,41) and a second runner (32,42) that are intertwined and helically wound around each other in a double helix that forms a toroidal shape, the toroidal shape having a center, wherein the toroidal shape is bisected by a plane that includes the center and divides the toroidal shape into two similar circular halves; and a first conductive wire spirally wound around the first runner (31,41); and a second conductive wire spirally wound around the second runner (32,42); and one or more power sources configured to provide one or more alternating currents to the first conductive wire, and configured to provide power to rotate the body (30,40,50,61) with respect to the support structure at more than one revolution per second, wherein the body (30,40,50,61) is rotatable around a rotational axis, wherein the rotational axis is positioned within the plane, wherein the rotational axis intersects the center, wherein the body (30,40,50,61) is configured to accommodate an organism near the center, and wherein the system is configured to generate an electromagnetic effect responsive to the one or more alternating current being provided. a support structure configured to support a body (30,40,50,61), wherein the body (30,40,50,61) is rotatable with respect to the support structure; the body (30,40,50,61) including: a first runner (31,41) and a second runner (32,42) that are intertwined and helically wound around each other in a double helix that forms a toroidal shape, the toroidal shape having a center, wherein the toroidal shape is bisected by a plane that includes the center and divides the toroidal shape into two similar circular halves; and a first conductive wire spirally wound around the first runner (31,41); and a second conductive wire spirally wound around the second runner (32,42); and one or more power sources configured to provide one or more alternating currents to the first conductive wire, and configured to provide power to rotate the body (30,40,50,61) with respect to the support structure at more than one revolution per second, wherein the body (30,40,50,61) is rotatable around a rotational axis, wherein the rotational axis is positioned within the plane, wherein the rotational axis intersects the center, wherein the body (30,40,50,61) is configured to accommodate an organism near the center, and wherein the system is configured to generate an electromagnetic effect responsive to the one or more alternating current being provided.
A method of using a biomarker panel to identify a rinse-off body wash composition that improves skin health, the method comprising: (a) non-surgically collecting control and test skin specimens and measuring in the specimens one or a combination of biomarkers from a panel of biomarkers whose presence in skin is correlated with at least one skin health measurement, the biomarker panel comprising inflammatory cytokines; wherein the control and test skin specimens both originate from the same source, and wherein the control skin specimen has been contacted with a control composition and the test skin specimen has been contacted with a rinse-off formulation test composition by application of said test composition to the test skin with subsequent rinsing therefrom within minutes; and (b) comparing the biomarker panel measurements in each of the control and test specimens; and (c) identifying the test composition as useful for improving skin health if there is a decrease in the log ratio of IL 1rα to IL 1α in the test specimen as compared to the control specimen. (a) non-surgically collecting control and test skin specimens and measuring in the specimens one or a combination of biomarkers from a panel of biomarkers whose presence in skin is correlated with at least one skin health measurement, the biomarker panel comprising inflammatory cytokines; wherein the control and test skin specimens both originate from the same source, and wherein the control skin specimen has been contacted with a control composition and the test skin specimen has been contacted with a rinse-off formulation test composition by application of said test composition to the test skin with subsequent rinsing therefrom within minutes; and (b) comparing the biomarker panel measurements in each of the control and test specimens; and (c) identifying the test composition as useful for improving skin health if there is a decrease in the log ratio of IL 1rα to IL 1α in the test specimen as compared to the control specimen.
A heat sink connector pin for attaching a heatsink to a top surface of a substrate and in thermal contact with a heat generating device, the pin comprising: a pin assembly comprising a pin head at a first end and a plurality of moveable fingers (110a-110n) at a second end, a shaft structure operably engaged to the moveable fingers and to the pin head, the shaft structure configured for downward movement as the pin head moves downward, the plurality of moveable fingers configured to be in a retracted position that allows insertion of the second end through an opening in the substrate without deforming the moveable fingers and configured to mechanically extend in an outward position in a manner that positions the plurality of fingers to contact a bottom surface of the substrate, in response to downward movement of the shaft structure.
An oral composition comprising the following components,, and: an olefin sulfonate having 14 or more and 20 or less carbon atoms; a hydroxy alkane sulfonate having 14 or more and 20 or less carbon atoms; and sorbitol, wherein the content of the component is 3 mass% or more and 50 mass% or less based on the total content of the component and the component. an olefin sulfonate having 14 or more and 20 or less carbon atoms; a hydroxy alkane sulfonate having 14 or more and 20 or less carbon atoms; and sorbitol,